Dec 19, 2023 Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
Dec 6, 2023 Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
Oct 2, 2023 Syros Announces Planned CEO Leadership Transition and Strategic Reorganization to Support Long-Term Business Growth and Maturation into a Commercial Biopharmaceutical Company